<!DOCTYPE html>
<html lang="en">
<head>
  <!-- Google tag (gtag.js) -->
  <script async src="https://www.googletagmanager.com/gtag/js?id=G-LSRR4KW715"></script>
  <script>
    window.dataLayer = window.dataLayer || [];
    function gtag(){dataLayer.push(arguments);
    }
    gtag('js', new Date());

    gtag('config', 'G-LSRR4KW715');
  </script>


  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0" />
  <title>Case 17.6 - Disorders of Calcium Metabolism</title>

  <!-- Favicon -->
  <link rel="icon" type="image/png" href="../../assets/ShepTech logo.png">
  <link rel="apple-touch-icon" href="../../assets/ShepTech logo.png">

  <!-- Primary Meta Tags -->
  <meta name="title" content="Case 17.6 - Disorders of Calcium Metabolism | MD3 SCP Cases">
  <meta name="description" content="Medical case study for MD3 students.">

  <!-- Open Graph / Facebook -->
  <meta property="fb:app_id" content="your_facebook_app_id">
  <meta property="og:type" content="article">
  <meta property="og:title" content="Case 17.6 - Disorders of Calcium Metabolism">
  <meta property="og:site_name" content="MD3 SCP Cases">
  <meta property="og:description" content="Medical case study for MD3 students.">
  <meta property="og:image" content="https://md3-scp.netlify.app/assets/ShepTech%20logo.png">
  <link rel="stylesheet" href="../../css/case.css">

  <!-- Firebase SDK -->
  <script src="https://www.gstatic.com/firebasejs/9.22.0/firebase-app-compat.js"></script>
  <script src="https://www.gstatic.com/firebasejs/9.22.0/firebase-auth-compat.js"></script>
  <script src="https://www.gstatic.com/firebasejs/9.22.0/firebase-firestore-compat.js"></script>
</head>
<body>
  <div class="container">
    <div class="case-header">
      <a href="#" class="back-link" onclick="goBack(event)">← Back to Cases</a>
    </div>

    <h1>Case 17.6 – Disorders of Calcium Metabolism</h1>
    <p class="meta"><strong>Category:</strong> Endocrine & Reproductive Systems | <strong>Discipline:</strong> Medicine - Endocrinology | <strong>Setting:</strong> General Practice</p>

    <h2>Case</h2>
    <p>Austin Solomon, 40 years old presents for follow-up of his blood test results. He has a history of recurrent renal tract calculi.</p>
    <p>His renal function is normal. His adjusted serum calcium which is <strong>3.20 mmol/l</strong> [2.2-2.6 mmol/L] and his serum phosphate level <strong>0.65 mmol/L</strong> [0.7 – 1.4 mmol/L].</p>

    <h2>Questions</h2>

    <div class="question">
      <strong>1. In further assessing Austin's results what key features of history and examination would you explore?</strong><br>
      <button class="toggle">Show Answer</button>
      <div class="answer">
        <p><strong>Symptoms and signs of hypercalcaemia include:</strong></p>
        <ul>
          <li>Polyuria and polydipsia</li>
          <li>Renal colic</li>
          <li>Lethargy</li>
          <li>Anorexia</li>
          <li>Nausea</li>
          <li>Dyspepsia and peptic ulceration</li>
          <li>Constipation</li>
          <li>Depression</li>
          <li>Drowsiness and impaired cognition</li>
        </ul>

        <p><strong>Malignant hypercalcaemia:</strong></p>
        <ul>
          <li>Patients can have a rapid onset of symptoms</li>
          <li>May have clinical features that help to localise the tumour</li>
        </ul>

        <p><strong>Primary hyperparathyroidism:</strong></p>
        <ul>
          <li>Patients may have a chronic, non-specific history</li>
          <li>Symptoms described by the adage '<strong>bones, stones and abdominal groans</strong>'</li>
          <li>About 50% of patients with primary hyperparathyroidism are asymptomatic</li>
          <li>In others, symptoms may go unrecognised until patients present with renal calculi:
            <ul>
              <li>5% of first stone formers have primary hyperparathyroidism</li>
              <li>15% of recurrent stone formers have primary hyperparathyroidism</li>
            </ul>
          </li>
          <li>Hypertension is common in hyperparathyroidism</li>
          <li>Parathyroid tumours are almost never palpable</li>
          <li>A family history of hypercalcaemia raises the possibility of FHH (familial hypocalciuric hypercalcaemia) or MEN (multiple endocrine neoplasia)</li>
        </ul>
      </div>
    </div>

    <div class="question">
      <strong>2. You consider that Austin that may have hyperparathyroidism, in reviewing the physiology of calcium metabolism outline how this would explain Austin's results.</strong><br>
      <button class="toggle">Show Answer</button>
      <div class="answer">
        <p><strong>Normal calcium metabolism:</strong></p>
        <ul>
          <li><strong>Oral intake:</strong> Calcium from diet</li>
          <li><strong>Vitamin D:</strong> Obtained from sunlight on skin and diet</li>
          <li><strong>Liver:</strong> Vitamin D 25-hydroxylase converts vitamin D to 25(OH) vitamin D (inactive)</li>
          <li><strong>Kidney:</strong> Vitamin D 1α-hydroxylase converts 25(OH) vitamin D to 1,25(OH)<sub>2</sub> vitamin D (active)</li>
          <li><strong>Active vitamin D actions:</strong>
            <ul>
              <li>Increases calcium absorption from gut</li>
              <li>Increases calcium reabsorption from bone</li>
              <li>Increases serum calcium</li>
            </ul>
          </li>
          <li><strong>Parathyroid glands:</strong> Have calcium-sensing receptors
            <ul>
              <li>When serum calcium is low, PTH secretion increases</li>
              <li>When serum calcium is high, PTH secretion decreases (negative feedback)</li>
            </ul>
          </li>
          <li><strong>PTH actions:</strong>
            <ul>
              <li>Stimulates bone resorption (releases calcium from bone)</li>
              <li>Increases renal calcium reabsorption</li>
              <li>Increases renal phosphate excretion</li>
              <li>Stimulates 1α-hydroxylase in kidney (increases active vitamin D)</li>
            </ul>
          </li>
        </ul>

        <p><strong>In hyperparathyroidism (explaining Austin's results):</strong></p>
        <ul>
          <li><strong>Elevated serum calcium (3.20 mmol/l):</strong> Due to excess PTH causing:
            <ul>
              <li>Increased bone resorption</li>
              <li>Increased renal calcium reabsorption</li>
              <li>Increased gut calcium absorption (via increased vitamin D activation)</li>
            </ul>
          </li>
          <li><strong>Low serum phosphate (0.65 mmol/L):</strong> Due to PTH increasing renal phosphate excretion
            <ul>
              <li>This is a key diagnostic feature - the PTH is causing phosphate wasting in the kidneys</li>
            </ul>
          </li>
          <li><strong>Recurrent renal calculi:</strong> Due to:
            <ul>
              <li>High serum calcium → hypercalciuria</li>
              <li>Calcium precipitates in urine forming stones</li>
            </ul>
          </li>
        </ul>
      </div>
    </div>

    <div class="question">
      <strong>3. Summarise the causes of hypercalcaemia and outline the further investigations [including imaging] that you would undertake to determine the cause of Austin's hypercalcaemia.</strong><br>
      <button class="toggle">Show Answer</button>
      <div class="answer">
        <p><strong>CAUSES OF HYPERCALCAEMIA:</strong></p>

        <p><strong>With normal or elevated (i.e. inappropriate) PTH levels:</strong></p>
        <ul>
          <li>Primary or tertiary hyperparathyroidism</li>
          <li>Lithium-induced hyperparathyroidism</li>
          <li>Familial hypocalciuric hypercalcaemia</li>
        </ul>

        <p><strong>With low (i.e. suppressed) PTH levels:</strong></p>
        <ul>
          <li><strong>Malignancy</strong> (e.g. lung, breast, renal, ovarian, colonic and thyroid carcinoma, lymphoma, multiple myeloma)</li>
          <li>Elevated 1,25(OH)<sub>2</sub> vitamin D (e.g. vitamin D intoxication, sarcoidosis, HIV)</li>
          <li>Thyrotoxicosis</li>
          <li>Paget's disease with immobilisation</li>
          <li>Milk-alkali syndrome</li>
          <li>Thiazide diuretics</li>
          <li>Glucocorticoid deficiency</li>
        </ul>

        <p><strong>INVESTIGATIONS:</strong></p>

        <p><em>Initial biochemistry:</em></p>
        <ul>
          <li><strong>Low plasma phosphate</strong> and <strong>elevated alkaline phosphatase</strong> support a diagnosis of primary hyperparathyroidism or malignancy</li>
          <li><strong>High plasma phosphate and alkaline phosphatase</strong> accompanied by renal impairment suggest tertiary hyperparathyroidism</li>
          <li>Hypercalcaemia may cause nephrocalcinosis and renal tubular impairment resulting in hyperuricaemia and hyperchloraemia</li>
        </ul>

        <p><em>Most discriminant investigation:</em></p>
        <ul>
          <li><strong>Measurement of PTH</strong> using a specific immunoradiometric assay:
            <ul>
              <li><strong>If PTH is normal or elevated</strong> and urinary calcium is elevated → hyperparathyroidism confirmed</li>
              <li><strong>Low urine calcium excretion</strong> indicates likely FHH (can be confirmed by screening family members for hypercalcaemia or genetic analysis of calcium-sensing receptor)</li>
              <li><strong>If PTH is low</strong> and no other cause is apparent → malignancy with or without bony metastases is likely</li>
            </ul>
          </li>
          <li>PTH-related peptide (often responsible for hypercalcaemia associated with malignancy) is not detected by modern PTH assays, but can be measured by a specific assay (though not usually necessary)</li>
        </ul>

        <p><em>Screen for malignancy if PTH is low:</em></p>
        <ul>
          <li>Chest X-ray</li>
          <li>Isotope bone scan</li>
          <li>Myeloma screen</li>
          <li>Serum angiotensin-converting enzyme (elevated in sarcoidosis)</li>
          <li>Further imaging as appropriate</li>
        </ul>
      </div>
    </div>

    <div class="question">
      <strong>4. Develop a flow chart summarising the investigation results [including imaging] that assist in determining the likely diagnosis.</strong><br>
      <button class="toggle">Show Answer</button>
      <div class="answer">
        <p><strong>Investigation pathway for hypercalcaemia:</strong></p>

        <p><strong>Step 1: Measure PTH</strong></p>

        <p><strong>If PTH is normal or elevated (inappropriate for high calcium):</strong></p>
        <ul>
          <li>Measure urinary calcium excretion:
            <ul>
              <li><strong>High urine calcium</strong> → <strong>Primary hyperparathyroidism</strong>
                <ul>
                  <li>Low plasma phosphate</li>
                  <li>Elevated alkaline phosphatase</li>
                  <li>May have renal stones</li>
                  <li>May have bone changes</li>
                </ul>
              </li>
              <li><strong>Low urine calcium</strong> → <strong>Familial hypocalciuric hypercalcaemia (FHH)</strong>
                <ul>
                  <li>Screen family members</li>
                  <li>Genetic testing of calcium-sensing receptor</li>
                </ul>
              </li>
            </ul>
          </li>
          <li>If renal impairment present with high phosphate → Consider <strong>tertiary hyperparathyroidism</strong></li>
        </ul>

        <p><strong>If PTH is low (suppressed):</strong></p>
        <ul>
          <li>Screen for malignancy:
            <ul>
              <li>Chest X-ray</li>
              <li>Bone scan</li>
              <li>Myeloma screen (serum/urine electrophoresis)</li>
              <li>PTH-related peptide if indicated</li>
            </ul>
          </li>
          <li>Check for other causes:
            <ul>
              <li>Vitamin D levels (intoxication, sarcoidosis)</li>
              <li>Thyroid function (thyrotoxicosis)</li>
              <li>Drug history (thiazides, vitamin D supplements)</li>
              <li>ACE level (sarcoidosis)</li>
            </ul>
          </li>
        </ul>
      </div>
    </div>

    <div class="question">
      <strong>5. In a table outline the types of hyperparathyroidism and the differences seen in serum calcium and PTH levels with each type.</strong><br>
      <button class="toggle">Show Answer</button>
      <div class="answer">
        <table>
          <tr>
            <th>Type</th>
            <th>Serum calcium</th>
            <th>PTH</th>
            <th>Details</th>
          </tr>
          <tr>
            <td><strong>Primary</strong></td>
            <td>Raised</td>
            <td>Not suppressed (inappropriately normal or elevated)</td>
            <td>
              <ul>
                <li>Single adenoma (90%)</li>
                <li>Multiple adenomas (4%)</li>
                <li>Nodular hyperplasia (5%)</li>
                <li>Carcinoma (1%)</li>
              </ul>
            </td>
          </tr>
          <tr>
            <td><strong>Secondary</strong></td>
            <td>Low</td>
            <td>Raised</td>
            <td>
              <ul>
                <li>Chronic renal failure</li>
                <li>Malabsorption</li>
                <li>Osteomalacia and rickets</li>
                <li>Low calcium → PTH glands increase activity</li>
              </ul>
            </td>
          </tr>
          <tr>
            <td><strong>Tertiary</strong></td>
            <td>Raised</td>
            <td>Not suppressed (inappropriately normal or elevated)</td>
            <td>
              <ul>
                <li>Progression from 2° hyperparathyroidism</li>
                <li>PTH glands increased activity → became autonomous</li>
                <li>Even when underlying cause treated, PTH glands continue over-secreting</li>
              </ul>
            </td>
          </tr>
        </table>
      </div>
    </div>

    <div class="question">
      <strong>6. Briefly outline the principles of management of hypercalcaemia.</strong><br>
      <button class="toggle">Show Answer</button>
      <div class="answer">
        <p><strong>TREATMENT OF SEVERE HYPERCALCAEMIA:</strong></p>

        <p><strong>1. Rehydration with normal saline</strong></p>
        <ul>
          <li>To replace as much as a 4-6 l deficit</li>
          <li>May need monitoring with central venous pressure in old age or renal impairment</li>
        </ul>

        <p><strong>2. Bisphosphonates</strong> (e.g. disodium pamidronate 90 mg i.v. over 4 hours)</p>
        <ul>
          <li>Inhibit osteoclast activity → osteoblast activity → take calcium from blood & deposit into bone</li>
          <li>Causes a fall in calcium which is maximal at 2-3 days and lasts a few weeks</li>
          <li>Unless the cause is removed, follow up with an oral bisphosphonate</li>
        </ul>

        <p><strong>3. Additional rapid therapy may be required in very ill patients:</strong></p>
        <ul>
          <li>Forced diuresis with saline and furosemide</li>
          <li>Glucocorticoids, e.g. prednisolone 40 mg daily</li>
          <li>Calcitonin (inhibits osteoclast activity - take calcium from blood & deposit into bone)</li>
          <li>Haemodialysis</li>
        </ul>

        <p><strong>4. Treat the cause</strong></p>

        <p><strong>Management of Primary Hyperparathyroidism:</strong></p>
        <ul>
          <li>Hypercalcaemia in patients with primary hyperparathyroidism responds less well to glucocorticoids and bisphosphonates than in those with malignancy</li>
          <li>Urgent neck surgery is occasionally required, but strenuous attempts should be made to replace fluid deficits and lower the serum calcium concentration before administering an anaesthetic</li>
        </ul>

        <p><strong>Long-term management of Primary Hyperparathyroidism:</strong></p>
        <ul>
          <li>Currently, the only long-term therapy is <strong>surgery</strong>, with excision of a solitary parathyroid adenoma or debulking of hyperplastic glands</li>
          <li><strong>Surgery is indicated for:</strong>
            <ul>
              <li>Young patients (\&lt;50 years)</li>
              <li>Those with clear-cut symptoms</li>
              <li>Documented complications: peptic ulceration, renal stones, renal impairment or osteopenia</li>
            </ul>
          </li>
          <li><strong>Patients with vague symptoms or asymptomatic:</strong>
            <ul>
              <li>Can be reviewed every 6-12 months</li>
              <li>Assessment of symptoms, renal function, serum calcium and bone mineral density</li>
              <li>Should be encouraged to maintain a high oral fluid intake to avoid renal stones</li>
            </ul>
          </li>
        </ul>
      </div>
    </div>

  </div>

  <!-- JavaScript -->  <script src="../../js/firebase-config.js"></script>
  <script src="../../js/dark-mode.js"></script>
  <script src="../../js/auth.js"></script>
  <script src="../../js/user-analytics.js"></script>
  <script src="../../js/analytics-integration.js"></script>
  <script src="../../js/completion-tracker.js"></script>
  <script src="../../js/flag-tracker.js"></script>
  <script src="../../js/case-interactions.js"></script>

  <script>
    // Toggle case completion
    function toggleCaseCompletion() {
      if (window.completionTracker) {
        const caseId = window.completionTracker.getCurrentCaseId();
        if (caseId) {
          window.completionTracker.toggleCompletion(caseId);
        
    }
      
    }
    
    }
// Toggle case flag
    function toggleCaseFlag() {
      console.log('toggleCaseFlag() function called');
      console.log('window.flagTracker exists:', !!window.flagTracker);

      if (!window.flagTracker) {
        console.error('window.flagTracker is not defined!');
        alert('Flag tracker not initialized. Please refresh the page.');
        return;
      
    }

      const caseId = window.flagTracker.getCurrentCaseId();
      console.log('Current case ID:', caseId);

      if (!caseId) {
        console.error('Could not get case ID');
        alert('Could not determine case ID');
        return;
      
    }

      console.log('Calling window.flagTracker.toggleCaseFlag with caseId:', caseId);
      window.flagTracker.toggleCaseFlag(caseId);
    
    }

    // Update case flag button state on page load
    document.addEventListener('DOMContentLoaded', () => {
      if (window.flagTracker) {
        setTimeout(() => {
          const caseId = window.flagTracker.getCurrentCaseId();
          if (caseId) {
            window.flagTracker.updateCaseFlagButton(caseId);
          
    }
        }, 100);
      
    }
    });
    
    }
  </script>

  <script src="../../js/case-page-tracker.js"></script>
</body>
</html>